Validating cancer drug targets

John D. Benson, Ying Nan P Chen, Susan A. Cornell-Kennon, Marion Dorsch, Sunkyu Kim, Magdalena Leszczyniecka, William R. Sellers, Christoph Lengauer

Research output: Contribution to journalArticlepeer-review

Abstract

A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is clinically effective and acts through the target against which it was designed. Nevertheless, it is desirable to declare an early-stage drug target as 'validated' before investing in a full-scale drug discovery programme dedicated to it. Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established.

Original languageEnglish (US)
Pages (from-to)451-456
Number of pages6
JournalNature
Volume441
Issue number7092
DOIs
StatePublished - May 25 2006
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Validating cancer drug targets'. Together they form a unique fingerprint.

Cite this